<DOC>
	<DOCNO>NCT02569463</DOCNO>
	<brief_summary>The investigator evaluate effectiveness safeness low-dose Recombinant Human Interleukin-2 （rhIL-2） MAS .</brief_summary>
	<brief_title>Low-dose IL-2 ( Interleukin-2 ) Treatment Macrophage Activation Syndrome（MAS）</brief_title>
	<detailed_description>Autoimmune-associated macrophage activation syndrome ( MAS ) , also know secondary hemophagocytic lymphohistiocytosis ( HLH ) , rapidly progress life-threatening disease . VP16 ( Etoposide ) well-known standard therapy , associate substantial adverse effect , especially myelosuppression infection , steroid ciclosporin ( CSA ) always efficient disease . The investigator hypothesize low- dose IL-2 could novel therapy MAS . This clinical study test efficacy safety low dose IL-2 treatment MAS . The investigator perform single-centre pilot trial rhIL-2 MAS . The investigator evaluate effectiveness safeness low-dose IL-2 MAS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Macrophage Activation Syndrome</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Diagnosis Macrophage Activation Syndrome（MAS） MAS secondary autoimmune disease , Adult onset still 's disease ( AOSD ) , juvenile rheumatoid arthritis ( JRA ) Systemic Lupus Erythematosus ( SLE ) . Primary MAS Secondary neoplasia , lymphoma virus infection pretreatment Cyclosporine A relevant cardiac , pulmonary , neurologic psychiatric disease lifeVaccination within 4 week begin study medication pregnant breastfeeding weight 45kg 80kg</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>